| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-09-26 | Nouscom (Switzerland) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-09-26 | Pfizer (USA - NY) OncoImmune (USA - MD) | ONC-392 | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-09-26 | Inotec AMD (UK) | nomination |
Medical devices | Nomination | ||
| 2016-09-26 | Navidea Biopharmaceuticals (USA - OH) | nomination |
Infectious diseases | Nomination | ||
| 2016-09-25 | Philips (The Netherlands) IBA (Belgium) | diagnostic and therapeutic solutions for the treatment of cancer | cancer | collaboration |
Cancer - Oncology - Technology - Services | Collaboration agreement |
| 2016-09-23 | Allergan (Ireland) Rugen Therapeutics (China) | autism spectrum disorders, obsessive compulsive disorders | development |
Mental diseases - CNS diseases | Development agreement | |
| 2016-09-23 | Merck KGaA (Germany) | nomination |
Nomination | |||
| 2016-09-23 | BiolineRx (Israel) BGN Technologies, the Technology Transfer Company of Ben-Gurion University (Israel) Hadasit, the Technology Transfer Company of Hadassah Medical Organization (Israel) | BL-1220 (novel composition of sodium alginate) | liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH) | licensing |
Liver diseases - Hepatic diseases | Licensing agreement |
| 2016-09-22 | Evotec (Germany) Inserm Transfert (France) | new selective modulators of RhoB functions | collaboration R&D |
Cancer - Oncology | Collaboration agreement | |
| 2016-09-22 | TiGenix (Belgium) | nomination |
Nomination | |||
| 2016-09-22 | Galmed Pharmaceuticals (Israel) University of California, San Diego (USA - CA) | aramchol | non alcoholic fatty liver disease (NAFLD) | clinical research | Hepatic diseases - Liver diseases | Clinical research agreement |
| 2016-09-21 | Philips (The Netherlands) GAVI Alliance | scalable digital transformation plans to improve the quality of immunisation data | infectious diseases | development |
Infectious diseases | Development agreement |
| 2016-09-21 | Atyr Pharma (USA - CA) | nomination |
Nomination | |||
| 2016-09-21 | Philips (The Netherlands) | nomination |
Technology - Services - Medical devices | Nomination | ||
| 2016-09-21 | Merck KGaA (Germany) | packaging building in Darmstadt, Germany | construction of new premises |
Construction of new premises | ||
| 2016-09-21 | 4SC (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-09-21 | Bayer Healthcare (Germany) Evotec (Germany) | kidney diseases such as chronic kidney disease in diabetes patients | development |
Kidney diseases - Renal diseases | Development agreement | |
| 2016-09-21 | Affilogic (France) Takeda Pharmaceutical (Japan) | Nanofitins® platform | CNS diseases | R&D collaboration |
CNS diseases | R&D agreement |
| 2016-09-21 | Redhill Biopharma (Israel) IntelGenx (Canada) Pharmatronic Co (Republic of Korea) | Rizaport® (formerly RHB-103 - oral thin film formulation of rizatriptan) | acute migraines | licensing commercialisation |
CNS diseases | Licensing agreement |
| 2016-09-21 | Abeona Therapeutics (USA - NY) The University of North Carolina (USA - NC) | AIM ™ vector system | Batten disease | licensing |
Rare diseases - Genetic diseases - Neurological diseases - Neurodegenerative diseases | Licensing agreement |
